11/21/2024

Janusmed kön och genus

Janusmed kön och genus – Efient

Janusmed kön och genus är ett kunskapsstöd som tillhandahåller information om köns- och genusaspekter på läkemedelsbehandling. Kunskapsstödet är avsedd främst för hälso- och sjukvårdspersonal. Texterna är generella och ska inte ses som behandlingsriktlinjer. Det är alltid behandlande läkare som ansvarar för patientens medicinering.

För att komma till startsidan för Janusmed kön och genus och för att göra sökningar klicka här.

Tillbaka till index
A A
A A

Prasugrel

Prasugrel

Klass : A

Visa all info

Skriv ut

Kontakta oss

  1. Efient (prasugrel). Summary of Product Chracteristics. European Medicines Agency (EMA) [updated 2018-12-10, cited 2018-12-21].

  2. Efient (prasugrel). DailyMed [www]. US National Library of Medicine. [updated 2018-03-09, cited 2018-12-21].

  3. Wrishko RE, Ernest CS, Small DS, Li YG, Weerakkody GJ, Riesmeyer JR et al. Population pharmacokinetic analyses to evaluate the influence of intrinsic and extrinsic factors on exposure of prasugrel active metabolite in TRITON-TIMI 38. J Clin Pharmacol. 2009;49:984-98.

  4. Lau ES, Braunwald E, Murphy SA, Wiviott SD, Bonaca MP, Husted S et al. Potent P2Y12 Inhibitors in Men Versus Women: A Collaborative Meta-Analysis of Randomized Trials. J Am Coll Cardiol. 2017;69(12):1549-1559.

  5. Lee KK, Welton N, Shah AS, Adamson PD, Dias S, Anand A et al. Differences in relative and absolute effectiveness of oral P2Y12 inhibition in men and women: a meta-analysis and modelling study. Heart. 2018;104(8):657-664.

  6. Roe MT, Armstrong PW, Fox KA, White HD, Prabhakaran D, Goodman SG et al. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med. 2012;367:1297-309.

  7. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001-15.

  8. Almendro-Delia M, Blanco Ponce E, Gomez-Domínguez R, Gonzalez-Matos C, Lobo-Gonzalez M, Caballero-Garcia A et al. Safety and efficacy of in-hospital clopidogrel-to-prasugrel switching in patients with acute coronary syndrome An analysis from the 'real world'. J Thromb Thrombolysis. 2015;39(4):499-507.

  9. Widimsky P, Motovska Z, Bolognese L, Dudek D, Hamm C, Tanguay JF et al. Predictors of bleeding in patients with acute coronary syndromes treated with prasugrel. Heart. 2015;101(15):1219-24.

  10. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2017 [cited 2018-12-17.]

  1. Efient (prasugrel). Summary of Product Chracteristics. European Medicines Agency (EMA) [updated 2018-12-10, cited 2018-12-21].
  2. Efient (prasugrel). DailyMed [www]. US National Library of Medicine. [updated 2018-03-09, cited 2018-12-21].
  3. Wrishko RE, Ernest CS, Small DS, Li YG, Weerakkody GJ, Riesmeyer JR et al. Population pharmacokinetic analyses to evaluate the influence of intrinsic and extrinsic factors on exposure of prasugrel active metabolite in TRITON-TIMI 38. J Clin Pharmacol. 2009;49:984-98.
  4. Lau ES, Braunwald E, Murphy SA, Wiviott SD, Bonaca MP, Husted S et al. Potent P2Y12 Inhibitors in Men Versus Women: A Collaborative Meta-Analysis of Randomized Trials. J Am Coll Cardiol. 2017;69(12):1549-1559.
  5. Lee KK, Welton N, Shah AS, Adamson PD, Dias S, Anand A et al. Differences in relative and absolute effectiveness of oral P2Y12 inhibition in men and women: a meta-analysis and modelling study. Heart. 2018;104(8):657-664.
  6. Roe MT, Armstrong PW, Fox KA, White HD, Prabhakaran D, Goodman SG et al. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med. 2012;367:1297-309.
  7. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001-15.
  8. Almendro-Delia M, Blanco Ponce E, Gomez-Domínguez R, Gonzalez-Matos C, Lobo-Gonzalez M, Caballero-Garcia A et al. Safety and efficacy of in-hospital clopidogrel-to-prasugrel switching in patients with acute coronary syndrome An analysis from the 'real world'. J Thromb Thrombolysis. 2015;39(4):499-507.
  9. Widimsky P, Motovska Z, Bolognese L, Dudek D, Hamm C, Tanguay JF et al. Predictors of bleeding in patients with acute coronary syndromes treated with prasugrel. Heart. 2015;101(15):1219-24.
  10. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2017 [cited 2018-12-17.]